Yeramian Patrick D 4
4 · Amylyx Pharmaceuticals, Inc. · Filed May 17, 2023
Insider Transaction Report
Form 4
Yeramian Patrick D
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2023-05-15$0.37/sh+2,201$814→ 210,618 total - Sale
Common Stock
2023-05-15$29.03/sh−11,965$347,358→ 208,417 total - Exercise/Conversion
Stock Option (right to buy)
2023-05-15−2,201→ 15,404 totalExercise: $0.37Exp: 2029-03-18→ Common Stock (2,201 underlying) - Exercise/Conversion
Common Stock
2023-05-15$6.88/sh+9,764$67,176→ 220,382 total - Exercise/Conversion
Stock Option (right to buy)
2023-05-15−9,764→ 33,770 totalExercise: $6.88Exp: 2031-02-21→ Common Stock (9,764 underlying)
Footnotes (4)
- [F1]These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.00 to $29.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]As of the date of this filing, 2,201 shares subject to the option are vested and exercisable. 15,404 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023.
- [F4]As of the date of this filing, 13,746 shares subject to the option are vested and exercisable. 23,600 shares subject to such option vest and become exercisable in substantially equal monthly installments until December 19, 2023.